JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JSKN-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JSKN-003 overview

JSKN-003 is under development for the treatment of solid tumors and HER positive breast cancer, non-small cell lung cancer, gastroesophageal junction adenocarcinoma, metastatic breast cancer, gastroesophageal borderline cancer, gastric cancer, ovarian cancer, head and neck cancer, lung cancer, esophageal cancer, breast cancer, stomach cancer and pancreatic cancer. It acts by targeting HER2. The drug candidate is being developed based on Glycan-specific conjugation platform, bispecific antibody drug conjugation (BADC). It is administered through intravenous drip route. It was also under development for bile duct cancer (cholangiocarcinoma) and metastatic colorectal cancer.

Alphamab Oncology overview

Alphamab Oncology (Alphamab) is a clinical-stage biopharmaceutical company that discovers, develops, manufactures and commercializes therapeutics for the treatment of cancer. The company’s pipeline products include KN035; an injectable PD-L1 inhibitor for the treatment of dMMR and MSI-H solid tumors, KN046; a BsAb immune checkpoint inhibitor, KN026; an anti-HER2 bispecific antibody. It also comprises KN019; a CTLA-4-based immunosuppressant fusion protein drug candidate used for treating indications such as autoimmune diseases and induced immune disorders. Alphamab offers JSKN-003, JSKN-001, JSKN-002, JSKN-004, JSKN-005, JSKN-006 and JSKN-008. The company appears its proprietary CRIB and CRAM platforms for bispecific and protein engineering and antibody screening to best-in-class medicines in oncology. Alphamab is headquartered in Suzhou, Jiangsu, China.

For a complete picture of JSKN-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.